Home
Intellia Therapeutics and SparingVision Strategic Collaboration to Develop Novel Ocular Therapies. See Also: Crispr Therapeutics’ News is Good, Not Bad

Intellia Therapeutics and SparingVision Strategic Collaboration to Develop Novel Ocular Therapies. See Also: Crispr Therapeutics’ News is Good, Not Bad

Impacting News October 14, 2021

Intellia Therapeutics and SparingVision Collaboration
Intellia Therapeutics (NTLA) and SparingVision - a genomic medicine company developing vision saving treatments for ocular diseases, announced a strategic collaboration to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases.

Intellia Therapeutics is to grant SparingVision exclusive rights to Intellia . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Impacting News
, ,
October 14, 2021

Other Articles